Table 4.
WFA-sialylated MUC1, CA19-9, and CEA levels in the serum and bile specimens of the study patients with respect to cancer pathological stages and histology
| Serum sample | pStage | |||||
|---|---|---|---|---|---|---|
| I | II | III | IV | I + II | III + IV | |
| n | 23 | 51 | 78 | 151 | 74 | 229 |
| WFA-MUC1 (µL/mL) | 313 (130–680) |
397 (117–1411) |
301 (56–1910) |
377 (102–2000) |
336 (117–1411) |
346 (56–2000) |
| CA19-9 (U/mL) | 15 (5–301) |
33 (1–617) |
76 (2–1314) |
144 (1–1118)a,b |
20 (1–617) |
122 (1–1314)c |
| CEA (ng/mL) | 1.7 (0.6–6.3) |
1.9 (0.5–21) |
2.8 (0.3–71) |
2.7 (0.4–92.4)b |
1.9 (0.5–21.0) |
2.8 (0.3–92.4)c |
| Serum sample | Histology | |||||
|---|---|---|---|---|---|---|
| Pap | Well | Mod | Por | Pap + Well | Mod + Por | |
| n | 25 | 79 | 157 | 42 | 104 | 199 |
| WFA-MUC1 (µL/mL) | 313 (130–483) |
316 (117–1411) |
358 (56–2000) |
385 (112–2000) |
314 (117–1411) |
360 (56–2000) |
| CA19-9 (U/mL) | 22 (5–311) |
88 (1–949) |
86 (1–1118)a |
82 (1–1314)a |
52 (1–949) |
83 (1–1314)c |
| CEA (ng/mL) | 1.9 (0.5–6.3) |
2.4 (0.7–77.8) |
2.7 (0.3–92.4) |
2.4 (0.6–49.5) |
2.4 (0.5–77.8) |
2.7 (0.3–92.4) |
| Bile sample | pStage | |||||
|---|---|---|---|---|---|---|
| I | II | III | IV | I + II | III + IV | |
| n | 16 | 30 | 52 | 85 | 46 | 137 |
| WFA-MUC1 (nL/µg proteind) | 26 (11–61) |
30 (11–653) |
28 (10–197) |
25 (10–533) |
27 (11–653) |
27 (10–533) |
| CA19-9 (U/µg proteind) | 3290 (102–25357) |
2412 (0.1–11055) |
4011 (37–48807) |
3162 (47–50156) |
2986 (0.1–25357) |
3572 (37–50156) |
| Bile sample | Histology | |||||
|---|---|---|---|---|---|---|
| Pap | Well | Mod | Por | Pap + Well | Mod + Por | |
| n | 17 | 45 | 92 | 29 | 62 | 121 |
| WFA-MUC1 (nL/µg proteind) | 39 (11–653) |
22 (10–247) |
29 (10–533) |
23 (11–313) |
27 (10–653) |
26 (10–534) |
| CA19-9 (U/µg proteind) | 4183 (102–25357) |
3403 (37–48807) |
3167 (0.1–20156) |
3269 (45–16081) |
3451 (37–48807) |
3167 (1–50153) |
Values are expressed as medians (range)
Pap papillary carcinoma, Well well-differentiated carcinoma, Mod moderately differentiated carcinoma, Por poorly differentiated carcinoma, WFA Wisteria floribunda agglutinin, MUC1 mucin core polypeptide 1, CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen
*Adjusted by biliary protein concentration
a Significantly different from pStage I
b Different from pStage II
c Different from pStages I + II